INTRODUCTION AND OBJECTIVES: Radical Nephrectomy (RN) has been the standard of care for complex and locally advanced renal cell carcinoma (RCC). Partial Nephrectomy (PN) utilization has increased in recent years. Efficacy of PN in the setting of pT3a pathologic upstaged disease is controversial. We compared oncologic and functional outcomes of RN and PN in patients with upstaged pT3a RCC.
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METHODS: We performed a multicenter retrospective analysis of patients with cT1-2N0M0 RCC undergoing RN or PN upstaged to pT3a postoperatively. Primary outcome was Overall Survival (OS), with secondary outcomes being Recurrence Free Survival (RFS) and eGFR<60 at last follow-up. Multivariable analysis (MVA) was performed to identify predictive factors for oncologic outcomes. Kaplan Meier analyses (KMA) were obtained to elucidate survival outcomes.
RESULTS: 8,185 patients were analyzed (mean follow up 48 months). 945 (11.5%) were upstaged to pT3a [686 (72.6%) RN, 243 (25.7%) PN]. Patients undergoing PN were older (p[0.016) and had higher median RENAL score (10 vs. 9, p<0.001), though smaller tumor size (7.3 vs. 7.7 cm, p<0.001). PN was associated with decreased incidence of eGFR<60 at last follow up (39.6% vs. 59.5% for RN, p[0.008). MVA showed that increasing age was the only independent predictor of all-cause mortality (OR 1.14, 95% CI 1.014 e 1.293, p[0.029). KMA revealed 5-year OS for PN cT1/pT3a, RN cT1/pT3a, PN cT2/pT3a, RN cT2/pT3a of 64%, 65.2%, 56.4% and 55.2% respectively (p[0.059). KMA revealed 5-year RFS for PN cT1/pT3a, RN cT1/pT3a, PN cT2/pT3a, RN cT2/pT3a of 79%, 74%, 70% and 51% respectively (p<0.001).
CONCLUSIONS: PN did not adversely affect oncologic outcomes in select patients who are upstaged to pT3a RCC from cT1 or cT2 disease, and may provide renal functional benefit. The decision to proceed with RN vs. PN in patients at risk for T3a upstaging should be individualized and driven by tumor as well as functional risks.
Improvements with respect to RFS for PN are most likely driven by selection bias. METHODS: We reviewed our prospectively maintained multicenter database for patients who underwent robotic PN between January 2006 and January 2018. We included patients with available follow up eGFR of at least 6 months. Median follow up period was 14 months (IQR: 7-26). Patients were divided according to the growth pattern of the tumor into 3 groups. Baseline data, perioperative data, and renal functional outcome data were compared using chi-square, Fisher's test and Kruskal Wallis test. Multilevel linear mixed effect model was used to determine the association between change in eGFR over time and tumor growth pattern.
RESULTS: Completely endophytic tumors were more likely to have a smaller tumor size, have a higher tumor complexity, leading to a longer ischemia time. Baseline eGFR was significantly different across the 3 groups (<50% Endophytic, 77.39 vs >50% Endophytic, 82.43 vs Completely Endophytic, 85.67; P [0.007) . There was no significant difference in the development of De novo stage III CKD and eGFR; however, there was a significant difference in the last follow-up eGFR (71.18 vs 74.12 vs 77.58; P [0.029) which reflects the same pattern of baseline eGFR. In the multilevel linear mixed effects model controlling for age, renal score, ischemia type, ischemia time and tumor size, change in eGFR over time comparing <50% endophytic, >50% endophytic and completely endophytic was not significant.
CONCLUSIONS: This study shows a relatively similar pattern of renal functional preservation for tumors with different growth patterns. These findings suggest that nephron sparing surgery should be attempted for challenging completely endophytic renal masses to optimize renal function outcome.
